Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Spotlight: Manus Neurodynamica Hopes To Write The End Of Traditional Parkinson’s Diagnosis

Executive Summary

Manus Neurodynamica intends to launch a pen, which provides early and accurate diagnosis of Parkinson’s disease, to the UK and Benelux markets and has £5m in funding to date.

You may also be interested in...



Interview: What Does Breakthrough Designation Mean For Manus Neurodynamica?

Medtech Insight spoke to Rutger Zietsma, Manus Neurodynamica’ CEO, to learn about the next commercial steps for the company's Neuromotor Pen for differential diagnosis of neuromotor impairment.

Exec Chat: Manus Neurodynamica Will Augment Pharmaceutical Companies’ Drug Trials

Simple-to-use devices capable of recording a plethora of data could be used to speed up drug trials and improve drug delivery, according to Rutger Zietsma, of Manus Neurodynamica.

Start-up Spotlight: AMT Tackles Melanoma Diagnosis With AI

Stockholm-based AI Medical Technology is developing Dermalyser, which can help doctor’s diagnose skin cancer using images of moles and lesions. The company is initially focused on Sweden and the Netherlands, but hopes to soon expand into new European markets and the US.

Topics

UsernamePublicRestriction

Register

MT143403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel